| drug | Cefepime |
| classification | Third-generation cephalosporin antibiotic |
| pharmacokinetics | | absorption | Well absorbed after intramuscular or intravenous administration. Peak plasma levels achieved within 30-60 minutes. | | distribution | Distributes widely into tissues and fluids, including cerebrospinal fluid (CSF) with adequate CSF penetration. | | metabolism | Primarily excreted unchanged in the urine, with some metabolism occurring. | | elimination | Renal elimination; dose adjustments may be necessary in patients with renal impairment. |
|
| suggested dosage | | adult | Dosage varies depending on the infection and severity. Typical intravenous doses range from 0.5-1 g every 8-12 hours. Oral formulations are less common due to absorption issues. | | special considerations | Adjust dosages based on patient's renal function. Higher doses may be required for serious infections. |
|
| indications | | 1 | Community-acquired pneumonia | | 2 | Skin and soft tissue infections | | 3 | Intra-abdominal infections | | 4 | Urinary tract infections (UTIs) | | 5 | Sepsis and other serious systemic infections. |
|
| safety in pregnancy | | category b | Generally considered safe in pregnancy during the first and second trimesters. However, the risk/benefit should be carefully evaluated and monitored. | | third trimester | Potential risks to the fetus need further consideration and evaluation by a physician. |
|
| safety in breastfeeding | It is excreted in breast milk in small amounts; consideration of potential risks in breastfeeding infants may be required. |
| side effects | | 1 | Diarrhea | | 2 | Nausea | | 3 | Vomiting | | 4 | Headache | | 5 | Hypersensitivity reactions (rash, itching, anaphylaxis) | | 6 | Superinfections (e.g., yeast infections) | | 7 | Localized pain at injection site | | 8 | Hepatitis | | 9 | Nephrotoxicity |
|
| alternatives | |
| contraindications | | 1 | Known hypersensitivity to cephalosporins or other penicillins | | 2 | Severe renal impairment (requiring cautious use and dosage adjustments) |
|
| interactions | | 1 | Concurrent use of other nephrotoxic drugs can increase the risk of kidney damage. | | 2 | Concurrent use of drugs that affect renal function, such as aminoglycosides, needs careful monitoring. |
|
| warnings and precautions | | 1 | Monitor renal function, particularly in patients with pre-existing kidney disease. | | 2 | Closely observe for signs of hypersensitivity reactions (anaphylaxis) after administration of cefepime. | | 3 | Use caution when prescribing to patients with a history of gastrointestinal problems. | | 4 | Monitor blood counts during prolonged therapy. | | 5 | Monitor for potential superinfection and adjust therapy if needed. |
|
| additional informations | | patient specific dosing | The dosage should be tailored to the specific patient's age, weight, renal function, and severity of infection. This information is not a substitute for professional medical advice, and dosage should be determined by a healthcare provider. | | monitoring | Close monitoring of the patient's response to treatment is crucial. |
|
| patient details | |
| disclaimer | This information is for educational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment. |
